Tatiana R. Kameneva

Tatiana R. Kameneva

Auto-generated profile, based on publicly available information

Tatiana R. Kameneva

Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2025 in Safety and Risk of Pharmacotherapy
Verified
Journal Article
Open access
PDF file
MZM. V. Zhuravleva
M. V. Zhuravleva
SSS. Yu. Serebrova
S. Yu. Serebrova
EKE. V. Kuznetsova
E. V. Kuznetsova
TKT. R. Kameneva
T. R. Kameneva
AVA. V. Vlasova
A. V. Vlasova
EDE. Yu. Demchenkova
E. Yu. Demchenkova
INTRODUCTION. It is essential to monitor the efficacy and safety of medicinal products as part of post-marketing surveillance to identify, assess, and prevent adverse drug reactions (ADRs). The effectiveness of pharmacovigilance depends largely on healthcare professionals’ adherence to the requirements and timeframes for reporting information to regulatory authorities.AIM. This study aimed to identify and systematise the key aspects of pharmacovigilance through an analysis of experience in organising pharmacovigilance in Moscow-based healthcare institutions in 2018–2024 to determine the focus areas for implementing, monitoring, and improving the pharmacovigilance system operating in medical organisations.DISCUSSION. The significance of pharmacovigilance systems and the need for their continuous improvement are underpinned by experience in establishing pharmacovigilance databases, including the global VigiBase database, the European Union’s EudraVigilance database, and the Eurasian Economic Union’s database. The main pharmacovigilance tools include active surveillance and collection of unsolicited/solicited reports of suspected ADRs. The Russian Federal Service for Surveillance in Healthcare (Roszdravnadzor) has developed clear operational criteria for pharmacovigilance in medical organisations. These criteria require that medical organisations should have in-house regulations for collecting, registering, and reporting data on ADRs to Roszdravnadzor, appointing qualified persons responsible for pharmacovigilance, and obtaining access to the Pharmacovigilance database of Roszdravnadzor’s Automated Information System. This article provides a detailed description of tools for establishing an effective pharmacovigilance system in a medical organisation, as well as the focus areas for organising pharmacovigilance in medical organisations, identified by analysing the experience of a territorial entity of the Russian Federation.CONCLUSIONS. To improve the effectiveness of pharmacovigilance in medical organisations, it is necessary to ensure the quality, integrity, and completeness of data submitted in spontaneous ADR reports. Spontaneous reporting should be supplemented with active surveillance methods, including the Global Trigger Tool. The current pharmacovigilance system in Moscow demonstrates a steady increase in reporting ADRs to Roszdravnadzor.

16 November 2025 in Medical alphabet
Verified
Journal Article
Open access
PDF file
M. Ya. YadgarovM. Ya. Yadgarov
M. Ya. Yadgarov
TKT. R. Kameneva
T. R. Kameneva
NBNatalia Vladimirovna Beloborodova
Natalia Vladimirovna Beloborodova
LBLevan Berikashvili
Levan Berikashvili
МЮМихаил Юрьев
Михаил Юрьев
МЮМ. Ю. Юрьев
М. Ю. Юрьев
Introduction. Sepsis in patients with prolonged or chronic critical illness is associated with a high mortality and prolonged exposure to antimicrobial therapy. However, data on the microbiological profile and trends in antimicrobial resistance in this population remain limited. Objective. To assess the microbiological profile, antimicrobial consumption, and dynamics of antimicrobial resistance in patients with sepsis who experienced prolonged stays in intensive care units (ICUs). Materials and methods. We performed an analysis of the Russian Intensive Care Dataset (RICD v2.0, FNCC RR, 2017–2024). The study included patients with confirmed sepsis according to Sepsis-3 criteria who remained in the ICU for ≥24 hours. Data on microbiological testing, antimicrobial prescriptions, and resistance patterns were extracted. Antimicrobial consumption was quantified using standardized units of DDD per 100 bed-days. Integrated resistance was assessed using the Drug Resistance Index (DRI). Results. A total of 336 patients were included (median age 64 years; male – 43.5 %, median ICU stay 44 days). The leading causative pathogens were Klebsiella pneumoniae and Pseudomonas aeruginosa. Between 2022 and 2024, consumption of aminoglycosides, cephalosporins, cotrimoxazole, linezolid, and tigecycline increased, while use of carbapenems, levofloxacin, and metronidazole declined. Resistance to ceftazidime-avibactam rose from 37 % to 87 % (p=0.004), whereas resistance rates decreased for tigecycline, vancomycin, and gentamicin (p<0.01). The overall DRI reached 32.6 % in 2022, 41.2 % in 2023, and 34.1 % in 2024. Conclusions. This study demonstrates persistently high levels of antimicrobial resistance among septic patients with prolonged ICU stays, with a predominance of Gram-negative pathogens in the etiological structure of infections. Every third empirical prescription of antibiotic therapy was accompanied by resistance of the infectious agent. These findings highlight the need for continuous microbiological surveillance, optimization of antimicrobial stewardship programs.

29 June 2025 in Physical and rehabilitation medicine, medical rehabilitation
Verified
Journal Article
Open access
PDF file
TKTatiana R. Kameneva
Tatiana R. Kameneva
SBSergey Bazanovich
Sergey Bazanovich
МЮМихаил Юрьев
Михаил Юрьев
MZMaria Zhdanova
Maria Zhdanova
MGMarina A. Golubeva
Marina A. Golubeva
ЮМЮрьев Михаил
Юрьев Михаил
BACKGROUND: Chronic critical illness is characterized by ventilator dependence, systemic inflammatory response, multiorgan failure, secondary sarcopenia, hypermetabolism and hypercatabolism, and protein–energy malnutrition. In this category of intensive care unit patients, lower respiratory tract infections remain a significant cause of adverse outcomes, prolonged hospital stays, and increased treatment costs. It is impossible to provide adequate empirical treatment of lower respiratory tract infections without knowing the etiology and resistance of the leading pathogens of this nosocomial infection in a specific department of a healthcare organization. AIM: The study aimed to characterize the etiology of lower respiratory tract infections in intensive care unit patients from 2020 to 2023, determine their antibiotic susceptibility, identify the most common resistance mechanisms of leading pathogens, and provide recommendations for optimizing antimicrobial therapy. METHODS: The study included patients with confirmed lower respiratory tract infections, primarily those with prolonged or chronic critical illnesses, from 2020 to 2023. The BD Phoenix 100 automated analyzer was used to identify the pathogens. Susceptibility was interpreted using EUCAST criteria. RESULTS: From 2020 to 2023, the top 10 pathogens responsible for lower respiratory tract infections in 1,007 patients were predominantly gram-negative microorganisms. For this period, the following trends were noted: an increase in Acinetobacter baumannii from 13.22% to 21.40% (p 0.001), and a decrease in Escherichia coli from 7.90% to 2.98% (p 0.001). From 2020 to 2023, the resistance of Klebsiella pneumoniae and Acinetobacter baumannii to carbapenems increased significantly, from 80.50% to 91.64% (p 0.001) and from 89.89% to 98.14% (p 0.001), respectively. Among carbapenemase-producing Klebsiella pneumoniae, resistance to colistin, tigecycline, and ceftazidime + avibactam increased from 4.95% to 9.00% (p 0.001), from 48.76% to 71.28% (p 0.001), and from 33.06% to 47.73% (p = 0.041), respectively. CONCLUSION: The predominant pathogens causing lower respiratory tract infections in intensive care unit patients included Gram-negative bacteria with a high level of antibiotic resistance. These bacteria included carbapenem-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. The etiological structure of lower respiratory tract infections and their antibiotic susceptibility in these patients should be evaluated to create local protocols for effective empirical antimicrobial therapy in each specific intensive care unit of a healthcare organization.

5 October 2025 in Physical and rehabilitation medicine, medical rehabilitation
Verified
Journal Article
Open access
PDF file
SBSergey Bazanovich
Sergey Bazanovich
МЮМихаил Юрьев
Михаил Юрьев
VGVictoria V. Gudozhnikova
Victoria V. Gudozhnikova
MZMaria Zhdanova
Maria Zhdanova
MGMarina A. Golubeva
Marina A. Golubeva
ЮМЮрьев Михаил
Юрьев Михаил
BACKGROUND: Bacteremia is a serious clinical condition that often precedes or accompanies sepsis and septic shock, which remain leading causes of hospital mortality worldwide. Understanding the epidemiology of bacteremia—including antimicrobial resistance patterns—and treatment principles is critical for improving outcomes in patients with chronic critical illness and severe brain injury. AIM: This study aimed to determine the profile of bacteremia in patients with severe brain injury in predominantly chronic critical illness admitted to intensive care units from 2018 to 2024 and their antibiotic susceptibility; to identify common resistance mechanisms of leading pathogens; and to formulate recommendations for optimizing antimicrobial therapy in this population. METHODS: The study included patients with severe brain injury in predominantly chronic critical illness who developed clinically significant bacteremia. Microorganisms were identified, and antibiotic susceptibility was determined using the BD Phoenix 100 automated analyzer. Susceptibility interpretation followed EUCAST criteria. RESULTS: Among 292 patients in predominantly chronic critical illness, the top ten bacteremia pathogens were primarily Gram-negative organisms, including Klebsiella pneumoniae (40.11%), Pseudomonas aeruginosa (6.22%), Proteus/ Providencia spp. (5.94%), Acinetobacter baumannii (5.37%), Serratia marcescens (4.24%), Escherichia coli (3.10%), and Enterobacter cloacae (1.69%). During this period, high carbapenem resistance was observed in Klebsiella pneumoniae (84.29%) and Pseudomonas aeruginosa (61.90%). Among Gram-positive organisms, coagulase-negative staphylococci predominated (21.47%). CONCLUSION: Gram-negative bacteria with high levels of antibiotic resistance, including carbapenem-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa, were the predominant pathogens in bacteremia among patients with chronic critical illness in intensive care units. Establishing effective empirical antimicrobial therapy protocols requires analysis of local antibiotic susceptibility data.

30 April 2022 in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
Verified
Journal Article
Open access
PDF file
MZM. V. Zhuravleva
M. V. Zhuravleva
GKG. V. Kukushkin
G. V. Kukushkin
ELE. V. Luchinina
E. V. Luchinina
TST. V. Shelekhova
T. V. Shelekhova
TKT. R. Kameneva
T. R. Kameneva
ELE. A. Luchinin
E. A. Luchinin
Анализ стоимости лечения адеметионином больных внутрипечёночным холестазом и неалкогольной жировой болезнью печени

30 December 2023 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
MZM. V. Zhuravleva
M. V. Zhuravleva
KKK. A. Kokushkin
K. A. Kokushkin
ELE. V. Luchinina
E. V. Luchinina
TKT. R. Kameneva
T. R. Kameneva
EKE. V. Kuznetsova
E. V. Kuznetsova
LZLiudmila Zhukova
Liudmila Zhukova
Objective: to assess budget impact of using empegfilgrastim for the prevention of febrile neutropenia in patients with early and locally advanced human epidermal growth factor receptor 2 positive (HER2+) breast cancer who receive neoadjuvant “docetaxel / carboplatin / trastuzumab + pertuzumab” regimen, considering possible subsequent adjuvant therapy with trastuzumab emtansine or trastuzumab within the Russian healthcare system.Material and methods. We searched and analyzed published clinical, epidemiological and pharmacoeconomic studies as well as regulatory and legal documents. A decision tree model was constructed to reflect the probabilities of switching to different adjuvant therapy regimens depending on the achievement of pathomorphological complete response in patients with early and locally advanced HER2+ breast cancer. The budget impact analysis was carried out comparing two primary prophylactic options, empegfilgrastim and filgrastim.Results. Despite the higher costs of prevention with empegfilgrastim compared to filgrastim (249 vs. 134 thousand rubles), due to the higher rate of achieving a pathomorphological complete response and, accordingly, fewer cases requiring adjuvant therapy with the more expensive trastuzumab emtanzine, savings of 916 thousand rubles per 1 patient per 1 year of therapy are possible. In general, prophylaxis in the target population diagnosed with early and locally advanced HER2+ breast cancer using empegfilgrastim will result in a cost reduction of 9.4 billion rubles per 1 year compared to filgrastim.Conclusion. Empegfilgrastim prophylaxis, despite its higher annual cost, is an efficient option within the Russian healthcare system. In addition to reducing the incidence of febrile neutropenia, the frequency and dose of chemotherapy are preserved, resulting in increased efficacy of the primary therapy.